BrightSpring Drops 6.6% Despite 54% YTD Surge
BrightSpring Health Services has gained more than 54% year-to-date on the back of three consecutive EPS beats, but shares shed 6.6% in a single session last week and now sit at $60.30 — more than $12
BrightSpring Drops 6.6% Despite 54% YTD Surge
NEW YORK, September 15 —
BrightSpring Health Services, Inc. (BTSG) has beaten EPS estimates in three of four reported quarters, yet the CEO's July tax-withholding transaction of 56,319 shares disposed at $72.91 now sits 21% above the market. A fresh planned insider sale reported this week raises the question of whether a 54% YTD run has already priced in the improvement.
- EPS beat three of four quarters; most recent beat by 12.6%; trailing revenue $14.37B growing 23% YoY.
- CEO Jon B Rousseau disposed 56,319 shares at $72.91 on July 25; stock now trades at $60.30.
- Net debt $1.84B, gross margin 12.4%, forward P/E 26.5x, consensus price target $78.94.
Why the Multiple Is a Hostage to Growth
BrightSpring delivers specialty pharmacy services through the Pharmerica platform: infused, injectable, and oral medications. The Provider Services segment handles home-based clinical care including physical therapy and applied behavioral analysis. Medicare, Medicaid, and commercial insurers are the primary payers, and the 12.4% gross margin reflects the economics of specialty pharmacy distribution: high volume, low spread. At $14.37 billion in trailing revenue growing 23%, the scale is real, and $506 million in operating cash flow provides a buffer against the $1.84 billion net debt load. The test is whether growth sustains the 26.5x forward multiple; model those cash flows with a DCF calculator and the margin for error becomes clear.
The Selling Pattern
The insider picture warrants scrutiny. CEO Jon B Rousseau's tax-withholding disposition in late July, covering 56,319 shares at $72.91, was a procedural event tied to equity compensation rather than a discretionary sale. But the price is telling: that figure represents the value BrightSpring's own vesting schedule placed on shares now trading at $60.30. Scott A. Greenwell, President of Pharmerica, similarly disposed of shares via withholding in June. A planned $874,000 insider sale reported this week continues the pattern. None of these transactions is probative alone; together they represent insiders with full operational visibility choosing to hold less stock rather than more.
| Ticker | Mkt cap | Fwd P/E | 52-wk |
|---|---|---|---|
| BTSG | $11.9B | 26.5x | +121.9% |
| SNEX | $8.3B | 14.5x | +63.0% |
| PACS | $7.1B | 16.4x | +327.1% |
| WAY | $4.8B | 13.3x | -34.5% |
| INDV | $4.1B | 7.1x | +48.6% |
| CSTM | $3.4B | 9.1x | +66.8% |
What Breaks the Thesis Next Quarter
The consensus target of $78.94 implies more than 30% upside, and the EPS beat trajectory is real. The number that matters most next quarter is revenue growth: at 23% TTM, the 26.5x forward multiple is defensible; below 20%, the leverage math on $1.84 billion in net debt starts to press. BTSG also carries 8% short interest, enough to fuel a sharp move if Q3 delivers another double-digit EPS beat, or amplify a selloff if it doesn't. The $12 gap between July's vesting price and today signals how much the run may have overshot. Run the free BrightSpring Health Services, Inc. deep-dive → to track the next quarterly checkpoint.
Basis Report is independent research for informational purposes. It is not investment advice and not a recommendation to buy or sell any security.
BrightSpring Health Services has gained more than 54% year-to-date on the back of three consecutive EPS beats, but shares shed 6.6% in a single session last week and now sit at $60.30 — more than $12 below the price at which CEO Jon B Rousseau's shares were disposed in July. A fresh planned insider stock sale, reported this week, arrives into that pullback.